Evaluation of ovulation and safety outcomes in a multi-center randomized trial of three 84 day ulipristal acetate regimens

Carolyn Westhoff; David F. Archer; Kurt T. Barnhart; Philip D. Darney; Melissa Gilliam; Jeffrey T. Jensen; Anita L. Nelson; Stephanie Teal; Michael A. Thomas; Jack W. Hu; Jill Brown; Diana Blithe

doi:10.1016/j.contraception.2022.04.002

Evaluation of ovulation and safety outcomes in a multi-center randomized trial of three 84 day ulipristal acetate regimens

Carolyn Westhoff, David F. Archer, Kurt T. Barnhart, Philip D. Darney, Melissa Gilliam, Jeffrey T. Jensen, Anita L. Nelson, Stephanie Teal, Michael A. Thomas, Jack W. Hu, Jill Brown, Diana Blithe

In: Contraception · 2022 · vol. 112 , pp. 54–60 · doi:10.1016/j.contraception.2022.04.002 · PMID:35430238 · W4223989408

article OA: closed CC0

Limited metadata. Only one source feed has indexed this record so far — no abstract, full text, or open-access copy is available through Endo Lab. The publisher's page (linked below) is the canonical location for the actual content. If you have institutional access, use "Find at my library".

View at publisher → View on OpenAlex View on PubMed

⚙ AI-generated summary by claude@2026-06, 2026-06-09 ⓘ

This multi-center trial evaluated ovulation and safety outcomes for three different 84-day regimens of ulipristal acetate.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

My notes (saved in your browser only)

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (4)

References (18)

A review of the endometrial histologic effects of progestins and progesterone receptor modulators in reproductive age women via openalex
Daily Low-Dose Mifepristone Has Contraceptive Potential by Suppressing Ovulation and Menstruation: A Double-Blind Randomized Control Trial of 2 and 5 mg per Day for 120 Days via openalex
Development of the selective progesterone receptor modulator CDB-2914 for clinical indications via openalex
Effects of the Progesterone Receptor Modulator VA2914 in a Continuous Low Dose on the Hypothalamic-Pituitary-Ovarian Axis and Endometrium in Normal Women: A Prospective, Randomized, Placebo-Controlled Trial via openalex
doi:10.1089/jwh.2011.2851 via openalex
doi:10.1097/01.aog.0000239440.02284.45 via openalex
doi:10.1210/clinem/dgz139 via openalex
W6673106512 via openalex
doi:10.1016/j.contraception.2011.02.009 via openalex
doi:10.1016/j.contraception.2011.10.003 via openalex
doi:10.1016/j.contraception.2009.04.011 via openalex
doi:10.1016/j.fertnstert.2018.06.044 via openalex
doi:10.1093/humrep/dem177 via openalex
doi:10.1097/aog.0b013e3181e79440 via openalex
doi:10.1016/j.contraception.2017.01.004 via openalex
doi:10.1016/j.fertnstert.2014.02.008 via openalex
doi:10.1016/j.contraception.2014.08.006 via openalex
doi:10.1056/nejmoa1103182 via openalex

Source provenance

openalex: last seen: 2026-05-11T06:37:04.871248+00:00

License: CC0 · commercial use OK

[1] Effects of the Progesterone Receptor Modulator VA2914 in a Continuous Low Dose on the Hypothalamic-Pituitary-Ovarian Axis and Endometrium in Normal Women: A Prospective, Randomized, Placebo-Controlled Trial 2007

[2] Daily Low-Dose Mifepristone Has Contraceptive Potential by Suppressing Ovulation and Menstruation: A Double-Blind Randomized Control Trial of 2 and 5 mg per Day for 120 Days 2002

[3] A review of the endometrial histologic effects of progestins and progesterone receptor modulators in reproductive age women 2015

[4] Development of the selective progesterone receptor modulator CDB-2914 for clinical indications 2003